{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:01:28Z","timestamp":1787907688023,"version":"build-2784847793"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.farma.2023.12.004","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T16:18:39Z","timestamp":1707495519000},"page":"299-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Exploring the impact of pharmacogenetics on personalized medicine: A systematic review"],"prefix":"10.1016","volume":"48","author":[{"given":"Laura","family":"Amaro-\u00c1lvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Cordero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Calleja-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.farma.2023.12.004_bb0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4067\/S0034-98872017000400009","article-title":"Clinical applications of pharmacogenomics","volume":"145","author":"Qui\u00f1ones","year":"2017","journal-title":"Rev Med Chil"},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3949\/ccjm.87a.19073","article-title":"Pharmacogenomics: an evolving clinical tool for precision medicine","volume":"87","author":"Hockings","year":"2020","journal-title":"Cleve Clin J Med"},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.farma.2023.12.004_bb0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/cpt.2327","article-title":"Moving pharmacogenetics into practice: it's all about the evidence!","volume":"110","author":"Luzum","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.farma.2023.12.004_bb0025","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s12325-022-02067-8","article-title":"Genotype-guided prescription of azathioprine reduces the incidence of adverse drug reactions in TPMT intermediate metabolizers to a similar incidence as normal metabolizers","volume":"39","author":"Casaj\u00fas","year":"2022","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.farma.2023.12.004_bb0030","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3748\/wjg.v24.i8.941","article-title":"Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease","volume":"24","author":"Wang","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.farma.2023.12.004_bb0035","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/cts.13376","article-title":"Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators","volume":"15","author":"Cavallari","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.farma.2023.12.004_bb0040","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/pme.12380","article-title":"Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness","volume":"15","author":"Linares","year":"2014","journal-title":"Pain Med"},{"issue":"10","key":"10.1016\/j.farma.2023.12.004_bb0045","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/pgs-2021-0039","article-title":"Novel associations between CYP2B6 polymorphisms, perioperative methadone metabolism and clinical outcomes in children","volume":"22","author":"Packiasabapathy","year":"2021","journal-title":"Pharmacogenomics."},{"issue":"5","key":"10.1016\/j.farma.2023.12.004_bb0050","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/cpt.2408","article-title":"Pharmacogenetic predictors of cannabidiol response and tolerability in treatment-resistant epilepsy","volume":"110","author":"Davis","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.farma.2023.12.004_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-8587(22)00340-0","article-title":"Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials","volume":"11","author":"Dawed","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.farma.2023.12.004_bb0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/cpt.567","article-title":"Variants in pharmacokinetic transporters and glycemic response to metformin: a metgen meta-analysis","volume":"101","author":"Dujic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.farma.2023.12.004_bb0065","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/jcpt.13804","article-title":"Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients","volume":"47","author":"Ebid","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00228-012-1330-6","article-title":"Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients","volume":"69","author":"Zhao","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0075","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11239-019-01962-2","article-title":"Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care","volume":"49","author":"Gulilat","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.farma.2023.12.004_bb0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-021-03146-5","article-title":"To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study","volume":"78","author":"Xia","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0085","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cts.13176","article-title":"Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations","volume":"15","author":"El Rouby","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.farma.2023.12.004_bb0090","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/cpt.1323","article-title":"Effect of CYP4F2, VKORC1, and CYP2C9 in influencing coumarin dose: a single-patient data meta-analysis in more than 15,000 individuals","volume":"105","author":"Danese","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.farma.2023.12.004_bb0095","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/jth.14211","article-title":"The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study","volume":"16","author":"Maagdenberg","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.farma.2023.12.004_bb0100","doi-asserted-by":"crossref","first-page":"E002602","DOI":"10.1161\/CIRCGEN.119.002602","article-title":"Genotype-guided dosing of warfarin in Chinese adults: a multicenter randomized clinical trial","volume":"13","author":"Guo","year":"2020","journal-title":"Circ Genom Precis Med."},{"issue":"1","key":"10.1016\/j.farma.2023.12.004_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/FPC.0000000000000417","article-title":"Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine","volume":"31","author":"Haas","year":"2021","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.farma.2023.12.004_bb0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/FPC.0000000000000396","article-title":"Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives","volume":"30","author":"Haas","year":"2020","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"10.1016\/j.farma.2023.12.004_bb0115","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/jce.13032","article-title":"Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers","volume":"27","author":"Abdelhady","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"3","key":"10.1016\/j.farma.2023.12.004_bb0120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cpt.667","article-title":"The effect of gene variants on levonorgestrel pharmacokinetics when combined with antiretroviral therapy containing efavirenz or nevirapine","volume":"102","author":"Neary","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.farma.2023.12.004_bb0125","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/jac\/dkz298","article-title":"Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART","volume":"74","author":"Neary","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.farma.2023.12.004_bb0130","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cpt.2039","article-title":"Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"109","author":"Lee","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.farma.2023.12.004_bb0135","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00228-020-03050-4","article-title":"Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice","volume":"77","author":"Russmann","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.farma.2023.12.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.002069","article-title":"Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Lee","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"6","key":"10.1016\/j.farma.2023.12.004_bb0150","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.clinthera.2019.04.037","article-title":"Influence of CYP450 enzymes, CES1, PON1, ABCB1 and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention procedure","volume":"41","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"Clin Ther"},{"issue":"15","key":"10.1016\/j.farma.2023.12.004_bb0155","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs-2020-0065","article-title":"Liver enzyme CYP2D6 gene and tardive dyskinesia","volume":"21","author":"Lu","year":"2020","journal-title":"Pharmacogenomics."},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/FTD.0000000000000695","article-title":"Therapeutic drug monitoring of olanzapine and cytochrome p450 genotyping in nonsmoking subjects","volume":"42","author":"Miroshnichenko","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.farma.2023.12.004_bb0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/cpdd.172","article-title":"Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment","volume":"4","author":"Shilbayeh","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.farma.2023.12.004_bb0170","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics","author":"Beunk","year":"2023","journal-title":"Eur J Hum Genet"},{"issue":"7","key":"10.1016\/j.farma.2023.12.004_bb0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40261-020-00921-7","article-title":"Effect of cytochrome P450 and ABCB1 polymorphisms on imatinib pharmacokinetics after single-dose administration to healthy subjects","volume":"40","author":"Pena","year":"2020","journal-title":"Clin Drug Investig"},{"issue":"4","key":"10.1016\/j.farma.2023.12.004_bb0180","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00280-013-2258-y","article-title":"Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients","volume":"72","author":"Kim","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.farma.2023.12.004_bb0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12885-018-4471-x","article-title":"Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy","volume":"18","author":"Limviphuvadh","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.farma.2023.12.004_bb0190","doi-asserted-by":"crossref","first-page":"27826","DOI":"10.1038\/srep27826","article-title":"Pharmacogenetics-guided phase I study of capecitabine on an intermittent schedule in patients with advanced or metastatic solid tumours","volume":"6","author":"Soo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.farma.2023.12.004_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2018.05.009","article-title":"Clinical and pharmacogenetic determinants of 5-fluorouracyl\/leucovorin\/irinotecan toxicity: results of the PETACC-3 trial","volume":"99","author":"Tejpar","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.farma.2023.12.004_bb0200","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/tpj.2014.16","article-title":"The effect of the UGT1A1\u221728 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis","volume":"14","author":"Dias","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"10.1016\/j.farma.2023.12.004_bb0205","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/psp4.12563","article-title":"Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype-derived activity scores","volume":"9","author":"Thomas","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.farma.2023.12.004_bb0210","first-page":"142","article-title":"Pharmacogenetic polymorphisms affecting bisoprolol response","author":"Casta\u00f1o-Amores","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.farma.2023.12.004_bb0215","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2019.06.026","article-title":"Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: an exploratory study in a Spanish population","volume":"54","author":"Dap\u00eda","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.farma.2023.12.004_bb0220","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"10.1016\/j.farma.2023.12.004_bb0225","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2014.04.009","article-title":"In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)\/PROSPER study","volume":"235","author":"Postmus","year":"2014","journal-title":"Atherosclerosis."},{"issue":"11","key":"10.1016\/j.farma.2023.12.004_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/genes11111335","article-title":"Genetic variants affecting anti-vegf drug response in polypoidal choroidal vasculopathy patients: a systematic review and meta-analysis","volume":"11","author":"D\u00edaz-Villamar\u00edn","year":"2020","journal-title":"Genes (Basel)"},{"issue":"9","key":"10.1016\/j.farma.2023.12.004_bb0235","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/bcp.13646","article-title":"Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy","volume":"84","author":"Klarica Domjanovi\u0107","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.farma.2023.12.004_bb0240","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine","volume":"38","author":"Wang","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.farma.2023.12.004_bb0245","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.pnpbp.2017.04.031","article-title":"Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine","volume":"77","author":"Gass\u00f3","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.6","article-title":"Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs","volume":"5","author":"Kato","year":"2015","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.farma.2023.12.004_bb0255","doi-asserted-by":"crossref","first-page":"88.e1","DOI":"10.1016\/j.jamda.2016.09.021","article-title":"CYP2C9 genotypes modify benzodiazepine-related fall risk: original results from three studies with meta-analysis","volume":"18","author":"Ham","year":"2017","journal-title":"J Am Med Dir Assoc"},{"issue":"7","key":"10.1016\/j.farma.2023.12.004_bb0260","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/pgs-2017-0014","article-title":"Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis","volume":"18","author":"Ovejero-Benito","year":"2017","journal-title":"Pharmacogenomics."},{"issue":"1","key":"10.1016\/j.farma.2023.12.004_bb0265","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/pgs-2017-0143","article-title":"Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis","volume":"19","author":"Ovejero-Benito","year":"2018","journal-title":"Pharmacogenomics."},{"issue":"2","key":"10.1016\/j.farma.2023.12.004_bb0270","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.farma.2023.12.004_bb0275","first-page":"3","article-title":"Personalized drug therapy: a new challenge for hospital pharmacy departments","volume":"45","author":"Bermejo-Vicedo","year":"2021","journal-title":"Farm Hosp"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:49:55Z","timestamp":1731631795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1130634324000035"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2023.12.004","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the impact of pharmacogenetics on personalized medicine: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}